HighTower Advisors
JUNO

HighTower Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

HighTower Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-9,272
Closed -$376K – 2182
2015
Q3 		$376K Buy
+9,272
New +$407K 0.01% 1344

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HighTower Advisors's JUNO Position: Q4 2015 in Review

HighTower Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2015, closing a stake of 9,272 shares — an estimated $376K sold.

HighTower Advisors first reported a position in JUNO in Q3 2015 and held it in 1 quarter. The position peaked at $376K in Q3 2015. 160 funds tracked by Wall St. Rank hold JUNO as of Q4 2015.

  • HighTower Advisors reported no remaining Juno Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • HighTower Advisors sold 9,272 Juno Therapeutics, Inc. shares in Q4 2015, an estimated $376K.
  • HighTower Advisors first reported a position in Juno Therapeutics, Inc. in Q3 2015 and held it in 1 quarter.
  • HighTower Advisors's Juno Therapeutics, Inc. position peaked at $376K in Q3 2015.
  • 160 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2015.

Based on HighTower Advisors's 13F filing for Q4 2015, filed 12 Feb 2016.